DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ZOMIG-ZMT

Summary for Tradename: ZOMIG-ZMT

Patents:0
Applicants:1
NDAs:1
Suppliers: see list3
drug
patent expirations by year for
 ZOMIG-ZMT

Clinical Trials for: ZOMIG-ZMT

Determine Central 5-HT1B Receptor Occupancy of ZOMIGĀ® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Status: Completed Condition: Migraine

ZAP, US. Zomig for Appropriate for Primary Care
Status: Completed Condition: Migraine

Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Status: Completed Condition: Migraine

Zomig - Treatment of Acute Migraine Headache in Adolescents
Status: Completed Condition: Migraine Headache; Adolescents

Efficacy and Tolerability of Zolmitriptan Nasal Spray
Status: Completed Condition: Migraine

Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine
Status: Completed Condition: Acute Migraine; Migraine Headache; Headache Disorders

Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury
Status: Completed Condition: Spinal Cord Injuries; Muscle Spasticity

Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Status: Completed Condition: Migraine

Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy
Status: Completed Condition: Migraine Disorders

Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Status: Completed Condition: Migraine Disorders

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
ZOMIG-ZMT
zolmitriptan
TABLET, ORALLY DISINTEGRATING;ORAL021231Feb 13, 2001RXNo<disabled><disabled>
Astrazeneca
ZOMIG-ZMT
zolmitriptan
TABLET, ORALLY DISINTEGRATING;ORAL021231Sep 17, 2001RXYes<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc